D M Gibo
Overview
Explore the profile of D M Gibo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wykosky J, Palma E, Gibo D, Ringler S, Turner C, Debinski W
Oncogene
. 2008 Sep;
27(58):7260-73.
PMID: 18794797
The ephrinA1 ligand exerts antioncogenic effects in tumor cells through activation and downregulation of the EphA2 receptor and has been described as a membrane-anchored protein requiring clustering for function. However,...
2.
Debinski W, Slagle-Webb B, Achen M, Stacker S, Tulchinsky E, Gillespie G, et al.
Mol Med
. 2002 Jan;
7(9):598-608.
PMID: 11778649
Background: Glioblastoma multiforme (GBM) is a hypervascularized and locally infiltrating brain tumor of astroglial origin with a very poor prognosis. An X-linked c-fos oncogene-inducible mitogenic, morphogenic, and angiogenic factor, endothelial...
3.
Debinski W, Slagle B, Gibo D, Powers S, Gillespie G
J Neurooncol
. 2000 Nov;
48(2):103-11.
PMID: 11083073
We have previously documented that the vast majority of high-grade gliomas over-express binding sites for interleukin 13 (IL13) in situ. We now extend this analysis to evaluate the distribution of...
4.
Debinski W, Gibo D
Mol Med
. 2000 Aug;
6(5):440-9.
PMID: 10952023
Background: The vast majority of patients with high-grade gliomas (HGG) over-express interleukin 4 (IL4)-independent binding sites for IL13 in situ. In addition, mutated IL13-based cytotoxins directed specifically toward glioma-associated sites...
5.
Debinski W, Gibo D, Slagle B, Powers S, Gillespie G
Int J Oncol
. 1999 Jul;
15(3):481-6.
PMID: 10427128
We have recently documented that the vast majority of patients with glioblastoma multiforme (GBM) over-express a receptor (R) for interleukin 13 (IL13) in situ. We have now evaluated further the...
6.
Debinski W, Gibo D, Hulet S, Connor J, Gillespie G
Clin Cancer Res
. 1999 Jun;
5(5):985-90.
PMID: 10353730
Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor-specific antigen or receptor that is expressed by a majority...
7.
Olson D, Gibo D
Exp Cell Res
. 1998 Jun;
241(1):134-41.
PMID: 9633521
The disruption of the normal expression of wnt-5a in cell lines and in tumors is becoming increasingly recognized as important in cell transformation and tumorigenesis. For example, in endometrial cancer...
8.
Debinski W, Gibo D, Obiri N, Kealiher A, Puri R
Nat Biotechnol
. 1998 May;
16(5):449-53.
PMID: 9592393
The vast majority of brain cancers (gliomas) express a receptor (R) for interleukin 13 (IL13). In order to achieve specific targeting of the IL13R in gliomas, we have mutagenized human...
9.
Debinski W, Gibo D, Puri R
Int J Cancer
. 1998 May;
76(4):547-51.
PMID: 9590132
Human brain cancers (gliomas) overexpress large numbers of a receptor for interleukin 13 (IL13), making this receptor an attractive target for anti-glioma therapies. We have recently proposed that the glioma-associated...
10.
Olson D, Gibo D, Saggers G, Debinski W, Kumar R
Cell Growth Differ
. 1997 Apr;
8(4):417-23.
PMID: 9101087
Wnt gene family members are thought to play an important role in cell growth and differentiation. When normal wnt gene expression is disrupted, there is the potential for cell transformation....